Research programme: cell and gene therapies - Baylor College of Medicine/Cell Medica

Drug Profile

Research programme: cell and gene therapies - Baylor College of Medicine/Cell Medica

Alternative Names: CAR-modified NKT cell therapy; Off-the-shelf allogeneic cell therapy; Off-the-shelf allogeneic NKT; T-cell receptor therapy - Cell Medica/Baylor College of Medicine

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Baylor College of Medicine
  • Developer Baylor College of Medicine; Cell Medica
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Gene transference; Immunostimulants; Natural killer cell receptor modulators; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 24 Aug 2016 Cell Medica in-licenses T Cell receptor technology from University College London
  • 17 Jun 2016 Cell Medica and Baylor College of Medicine enter into an exclusive licensing agreement and co-development agreement for cell and gene therapies for cancer
  • 17 Jun 2016 Baylor college of Medicine has patent protection for genetically engineered natural killer T-cells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top